A Critical Review on Floating Drug Delivery and Hydrodynamic Balanced Systems
Drugs with narrow absorption window in the gastrointestinal tract have poor absorption. Therefore, hydrodynamically balanced systems (HBS) have been developed, which prolong the gastric emptying time. Several techniques such as floating drug delivery system, low density systems, raft systems, mucoadhesive systems, high density systems, superporous hydrogels and magnetic systems, have been employed. Floating drug delivery systems have a bulk density less than gastric fluids and so, remain buoyant in the stomach for a prolonged period of time, releasing the drug slowly at the desired rate from the system. Dosage forms available as gastric floating systems include tablets, capsules, granules and microspheres. This review on GRDDS attempts to compile the available information with all the possible mechanisms used to achieve gastric retention.
2.Patel Geeta: floating drug delivery system: An Innovative Approach to prolong gastric retention Pharmaceutical Reviews. Pharmainfo.net 2007; 5.
3.Jain S K., Agrawal G P. And Jain N K: floating microspheres as drug delivery system: Newer Approaches, evaluation of porous carrier-based floating or list at microspheres for gastric delivery; AAPS Pharmascitech 2006;7: E54-E62.
4.Desai S. A Novel Floating Controlled Release Drug Delivery System Based on a Dried Gel Matrix Network [master’s thesis]. 1984 Jamaica, NY, St John’s University.
5.Vantrappen GR, Peeters TL, Janssens J. The secretory component of interdigestive migratory motor complex in man. Scand J Gastroenterol. 1979;14: 663-667.
6.Wilson CG, Washington N. The stomach: its role in oral drug delivery. In: Rubinstein MH, ed. Physiological Pharmacetical: Biological Barriers to Drug Absorption. Chichester, UK: Ellis Horwood; 1989:47-70.
7.Desai S, Bolton S. A floating controlled release drug delivery system: in vitro- in vivo evaluation. Pharm Res. 1993;10:1321-1325.
8.Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235-259.
9.Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci. 1994;83:18-24.
10.Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time of the Heidelberg capsules in humans: effect of varying food composition. Gastroenterology. 1985;89:392-397.
11.Bechgaard H, Ladefoged K. Distribution of pellets in gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J Pharm Pharmacol. 1978;30:690-692.
12.Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003 Web Site. 5th edition. May 2003. Available at: http://www.touchbriefings.com/cdps/cditem.cfm?NID=17&CID=5. Accessed: ctober 6, 2005.
13.Timmermans J, Gansbeke VB, Moes AJ. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Vol I. Proceedings of the 5th International Conference on Pharmacy Technology. Paris, France APGI. 1989. 42-51.
14.Yang L, Fassihi R. Zero order release kinetics from self correcting floatable configuration drug delivery system. J Pharm Sci. 1996;85:170-173.
15.Burns SJ, Attwood D, Barnwell SG. Assesment of a dissolution vessel designed for use with floating and erodible dosage forms. Int J Pharm. 1998;160:213-218.
16.Joseph NJ, Laxmi S, Jayakrishnan A. A floating type oral dosage from for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J Control Release. 2002;79:71-79.
17.Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. US patent 4,126,672. November 21, 1978.
18.Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as floating drug delivery system to increase the gastric residence of drugs. Drug Metab Rev. 2001;33:149-160.
19.Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Prepration and in vitro evaluation of floating and sustained-release kinetics. J Pharm Sci. 1991;80:1062-1066.
20.Ichikawa M, Watanabe S, Miyake Y. Granule remaining in stomach.
21.US patent 4 844 905. July 4, 1989.
22.Yang L, Esharghi J, Fassihi R. A new intra gastric delivery system for the treatment of helicobacter pylori associated gastric ulcers: in vitro evaluation. J Control Release. 1999;57:215-222.
23.Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev Ind Pharm. 2000; 26:857-866.
24.Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating drug delivery: effects of CO2 gas forming agents. Int J Pharm. 2002;239:81-91.
25.Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev Ind Pharm. 2002; 28:783-793.
26.Li S, Lin S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2001;2:E1.
27.Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluids. J Pharm Pharmacol. 1993;45: 21-24.
28.Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm.2000; 26:965-969.
29.Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process conditions on casein gelatin beads floating properties. Int J Pharm. 2000;198:157-165.
30.Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm. 2000; 210:45-49.
31.Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effect of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003;18:37-45.
32.Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M. Expandable gastroretentive therapeutic system with controlled active substance release in gastrointestinal tract. US patent 6 290 989. September 18, 2001.
33.El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral drug delivery system. Int J Pharm. 2001; 220:13-21.
34.Illum L, Ping H. Gastroretentive controlled release microspheres for improved drug delivery. US patent 6 207 197. March 27, 2001.
35.Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002; 241:279-292.
36.Vyas, S.P. & Khar: Targeted and Controlled Drug Delivery Novel Carrier System, CBS Publishers and Distributors, New Delhi, Ist Ed, 2002: 417-454.